Mymus (Simeticone)

Simeticone acts as a surfactant that reduces the surface tension of gas bubbles in the gastrointestinal tract. This causes small bubbles to merge into larger ones, which can be expelled more readily through belching or flatulence, thereby decreasing the overall volume of gas and associated discomfort.

The appropriate dose of Mymus is determined by a qualified healthcare professional based on the patient’s age, weight, and clinical condition. Prescribers set the dosage and frequency, and patients should follow the specific instructions provided on the prescription label or by their clinician.

Current data on simeticone use in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Mymus.

To order Mymus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Mymus (simeticone) is a non‑systemic surfactant that works by physically altering gas bubbles, whereas alternatives such as activated charcoal adsorb gases chemically. Simeticone generally has a rapid onset, minimal systemic absorption, and a low incidence of side effects, making it a preferred option for many clinicians.

Mymus should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and extreme heat. Ensure the container is tightly closed to maintain product stability throughout its shelf life.

Mymus is taken orally, typically in tablet or liquid form, as directed by a healthcare professional. The product should be swallowed with water or mixed with a small amount of liquid if a liquid formulation is provided. Do not crush or chew tablets unless specifically instructed.

While rare, serious adverse reactions can include severe allergic responses such as anaphylaxis, angioedema (swelling of the face, lips, or throat), and extensive skin rash. Patients experiencing difficulty breathing, swelling, or widespread rash should seek immediate medical attention.

Mymus should be avoided by individuals with a known hypersensitivity to simeticone or any of the product’s excipients. It is also not recommended for infants younger than two months without medical supervision. Patients with persistent or unexplained gastrointestinal symptoms should obtain a professional evaluation before use.